Lag Time to Benefit: Why Some Preventive Treatments Only Pay Off Later

Lag time to benefit is how long a preventive treatment has to be continued before it prevents one bad outcome across a group of people. Screening for breast and colorectal cancer, for instance, takes on the order of a decade before one death is prevented per thousand people screened, so the benefit mostly reaches those who live long enough to collect it. Reading this number alongside a person's life expectancy is how clinicians judge whether starting, continuing, or stopping a preventive therapy makes sense.

What lag time to benefit measures

Most conversations about a preventive drug or test ask a single question: does it work? Lag time to benefit asks a second, quieter question that matters just as much: how long does it take to work? It is the interval a treatment must be sustained before it prevents one additional adverse event across a defined group of people.

This is not the same as a treatment being slow-acting in the body. A statin changes cholesterol within weeks. But preventing a heart attack that would have happened is a statistical event that accrues over time, because only a small fraction of treated people were ever going to have that event in any given period. The benefit is real, but it is spread thin across many people and many months, and it takes time to add up to one prevented outcome you can point to.

The cancer screening example

A pooled analysis of randomized screening trials put concrete numbers on this idea. For breast cancer screening, on average across the included trials it took close to eleven years before one death was prevented for every thousand women screened. For colorectal cancer screening the figure was similar, roughly a decade per thousand people screened.

The authors drew a practical conclusion from their own data: screening for these cancers is best suited to people whose life expectancy is greater than about ten years. Below that horizon, a person is far more likely to experience the downsides of screening, such as false alarms, biopsies, and the detection of cancers that would never have caused harm, than to live long enough to gain the mortality benefit.

Not every treatment has a long lag

A long lag is not a universal feature of prevention. When the underlying risk is high, benefits accumulate faster. In people who already have cardiovascular disease, an analysis of intensive lipid-lowering trials estimated that the time needed to prevent one major cardiovascular event per hundred treated people was on the order of a year and a half, with the exact figure differing by the type of therapy added on top of a statin.

The lesson is that lag time to benefit is specific to the treatment and the population, not a fixed property of prevention in general. A high-risk person on a potent therapy may reach benefit quickly, while a low-risk person on the same drug waits far longer.

Why life expectancy is the hinge

Once you have a lag-time estimate, the decision turns on a comparison: how does the time to benefit sit against the person's remaining life expectancy? If a treatment needs a decade to prevent one event and a person is unlikely to live that long, the arithmetic of benefit largely disappears, even though the harms and daily burdens arrive immediately.

This reasoning does not single out older people by age alone. Someone of any age with a serious limiting illness may have a short horizon, and a healthy older person may have a long one. The framework is about time left and treatment lag, not a birthday.

How this informs starting and stopping

Lag time to benefit is one of the cleaner arguments in the deprescribing toolkit. It gives a defensible, evidence-based reason to reconsider a preventive medicine when a person's health trajectory changes, without implying the drug was ever a mistake. A therapy that made sense at one horizon can stop making sense at another.

This is educational framing, not a rule for any individual. Whether to begin, continue, or step down a specific preventive treatment is a decision for a person and their own clinician, weighing goals, other conditions, and preferences. The value of the concept is that it makes the trade-off explicit rather than leaving it unspoken.

Reading a lag-time estimate critically

These estimates are averages built from trial populations, and they come with wide confidence intervals. A figure like ten years to benefit often carries a plausible range spanning several years in either direction, which should temper any false precision.

Two other cautions help. First, the estimate depends on the absolute risk threshold chosen, such as preventing one event per thousand versus per hundred, so always ask which denominator is being used. Second, a population average is not a personal guarantee; it describes the group, not the individual. Read the number as a compass heading, not a stopwatch.